Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer

Abstract

Background The current study aimed to explore the value of cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-associated microRNAs combined with inflammatory factors in the differential diagnosis of non-small cell lung cancer (NSCLC). Methods A retrospective study including 245 NSCLC patients and 245 healthy controls was conducted on a testing group. A regression formula for NSCLC prediction was established based on the testing group. Two validation groups from two centres were used to assess the novel logistic regression model including 144 NSCLC patients and 144 healthy controls recruited from the Wuchang Hospital Affiliated to Wuhan University of Science and Technology, and 128 NSCLC patients and 128 healthy controls recruited from the Zhongnan Hospital of Wuhan University. Results Predictive software and dual-luciferase reporter assays showed that miR-155-5p and miR-630 could target CTLA4 expression. The miR-155-5p and miR-630 concentrations in the NSCLC patients were significantly lower, and the neutrophil to lymphocyte ratio, hypersensitive C-reactive protein (hs-CRP), interleukin 6, cytokeratin-19-fragment (CYFRA21-1), squamous cell carcinoma antigen (SCCA) concentrations and the smoking rate were significantly higher than that in healthy controls ( P < 0.05). A logistic regression model that included smoking, neutrophil to lymphocyte ratio, hs-CRP, interleukin 6, CYFRA21-1, SCCA, miR-155-5p and miR-630 was performed. This model presented a high discriminating value (AUC: 0.830, sensitivity/specificity: 74.6%/89.7%) than any single indicator. In the validation groups, this model still showed a high discriminating value (AUC = 0.838 with the internal validation group; AUC = 0.851 with the external validation group). Conclusion The current model has potential significance for the non-invasive diagnosis for NSCLC.

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review

“…Other efforts of using miRNA-based liquid biopsy for lung cancer early detection were made by using single miRNAs as biomarkers such as miR-17-19 [31], miR-20 [32], miRNA-21 [33][34][35][36][37][38][39][40][41][42], miR-25 [43], miR-29 [44], miR-30 [45], miR-31 [46], miR-125, miR-126 [47][48][49], miR-135 [50], miR-143 [51], miR-145 [32], miR-148/152 family [52], miR-153, miR-155 [36,53,54], miR-182, miR-183 [47], miR-185 [55], miR-184 [56], miR-200 [57], miRNA-210 [47,58], miR-221 [32], miR-223 [32,59], miR-328 [60], miR-339 [61], miR-411 [62], miR-486 [63], miR-499 [64], miR-519 [65], miR-770 [66], mi-R762 [67], microRNA-2355 [68], hsa-miR2116, hsa-miR449c and hsa-miR2117 [69]. These single biomarker-based approaches led to similar results, but the heterogeneity of the study and the lack of a validation...…”

Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring

“…Lung cancer is a common malignant tumor, with high morbidity and mortality rates, posing a serious threat to patient's health and life safety [1]. According to statistics [2], the morbidity and mortality rates of lung cancer in men occupy the first place among all malignancies, and in women, the morbidity ranks third and the mortality ranks second. Clinical data show that nonsmall cell lung cancer (NSCLC) is associated with approximately 85% of lung cancer, and many cases have progressed to the advanced stage at the time of diagnosis due to the insidious symptoms and missed diagnosis.…”